RxDoctor Payments Data

Sheila Dini, PA

Physician Assistant · Atlanta, GANPI 1003187709

Payments from drug & device makers

$1,386in general payments, 2019–2025

Across 48 payments — averaging $28.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$155
  • Daiichi Sankyo Inc.$140
  • Karyopharm Therapeutics Inc.$125
  • Johnson & Johnson$115
  • GSK$90
  • Takeda Pharmaceuticals U.S.A., Inc.$86
  • plus $675 from 19 others

What the payments were for

  • Food & beverage$1,23189%
  • Education$15511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,386 in reported general payments places this provider in the 70th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$14,205
Medicare patients
139
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide15$221,293
EliquisApixaban23$25,146
XareltoRivaroxaban13$18,990
Prochlorperazine Maleate19$480
Letrozole22$401
Ondansetron OdtOndansetron16$336
Ibandronate Sodium19$261
Dexamethasone12$230
ValacyclovirValacyclovir Hcl12$134
Gabapentin14$101
Lactulose12$86
Anastrozole11$74
Pantoprazole Sodium13$50
Trazodone Hcl13$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada, Xarelto$115$240,28328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →